PDCD1 and non-small cell lung carcinoma: The result was in agreement with the conclusions from a recent study, which was done to assess the efficacy among 761 lesions (58 liver metastases) in 214 NSCLC patients treated with PD-1 inhibitor monotherapy and that indicated that liver metastatic lesions showed the worst response [27].